Article
[Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Apr 2021
Zhu Guangsheng, Li Yongwen, Shi Ruifeng, Xu Songlin, Zhang Zihe, Cao Peijun, Chen Chen, Liu Hongyu, Chen Jun
Abstract excerpt
BACKGROUND: Lung cancer is a malignant with high incidence and mortality and adenocarcinoma is among the most popular subtypes. Epidermal growth factor receptor (EGFR) mutation is one of the most important driver mutations for lung adenocarcinoma and EGFR-tyrosine kinase inhibitor (TKI) will benefit those patients with sensitive EGFR mutations. Recently, immune checkpoint inhibitor (ICI) therapy, provide a new...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
